FOLH1 and prostate carcinoma: Examples of analogical use can be seen in the upregulated cell surface proteins, PSMA or SSTR2 (already approved as targets for both tumor imaging and therapy), using the same affinity ligand but with radioisotopes of different activities in advanced prostate cancer and neuroendocrine tumors, respectively.